Role of Shiga/Vero Toxins in Pathogenesis
- Authors: Fumiko Obata1, Tom Obrig2
- Editors: Vanessa Sperandio3, Carolyn J. Hovde4
-
VIEW AFFILIATIONS HIDE AFFILIATIONSAffiliations: 1: University of Maryland School of Medicine, Baltimore, MD 21201; 2: University of Maryland School of Medicine, Baltimore, MD 21201; 3: University of Texas Southwestern Medical Center, Dallas, TX; 4: University of Idaho, Moscow, ID
-
Received 01 May 2013 Accepted 29 July 2013 Published 20 June 2014
- Correspondence: Fumiko Obata, [email protected]
- « Previous Article
- Table of Contents
- Next Article »

-
Abstract:
Shiga toxin (Stx) is the primary cause of severe host responses including renal and central nervous system disease in Shiga toxin-producing Escherichia coli (STEC) infections. The interaction of Stx with different eukaryotic cell types is described. Host responses to Stx and bacterial lipopolysaccharide are compared as related to the features of the STEC-associated hemolytic-uremic syndrome (HUS). Data derived from animal models of HUS and central nervous system disease in vivo and eukaryotic cells in vitro are evaluated in relation to HUS disease of humans.
-
Citation: Obata F, Obrig T. 2014. Role of Shiga/Vero Toxins in Pathogenesis. Microbiol Spectrum 2(3):EHEC-0005-2013. doi:10.1128/microbiolspec.EHEC-0005-2013.




Role of Shiga/Vero Toxins in Pathogenesis, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/microbiolspec/2/3/EHEC-0005-2013-1.gif /docserver/preview/fulltext/microbiolspec/2/3/EHEC-0005-2013-2.gif

References

Article metrics loading...
Abstract:
Shiga toxin (Stx) is the primary cause of severe host responses including renal and central nervous system disease in Shiga toxin-producing Escherichia coli (STEC) infections. The interaction of Stx with different eukaryotic cell types is described. Host responses to Stx and bacterial lipopolysaccharide are compared as related to the features of the STEC-associated hemolytic-uremic syndrome (HUS). Data derived from animal models of HUS and central nervous system disease in vivo and eukaryotic cells in vitro are evaluated in relation to HUS disease of humans.

Full text loading...
Figures

Click to view
FIGURE 1
Schema: Shiga toxin interaction with eukaryotic cells.

Click to view
FIGURE 2
Proposed pathways of Stx and LPS actions in mice. Data derived from a Stx/LPS murine model of HUS indicate that LPS is the primary elicitor of fibrin deposition in kidneys. This pathway requires chemokines and platelets but is not responsible for renal failure. Stx is responsible for renal failure in this murine model in a process that involves nonendothelial renal cell types.

Click to view
FIGURE 3
Anti-inflammatory actions of adenosine in HUS. Data derived from an Stx/LPS murine model of HUS suggest adenosine A2a receptor agonist, i.e., adenosine, effectively blocks the actions of LPS (enhanced by Stx2) at the level of different renal cell types to prevent platelet activation and coagulation.

Click to view
FIGURE 4
Neutrophil-endothelial cell interactions in HUS. In the Stx2/LPS murine model of HUS, analysis of renal gene activation and neutrophil infiltration into kidneys demonstrates a concomitant increase in PMNs and VCAM-1 expression, suggesting a mechanism of PMN-endothelial association. ♦, Neutrophils in the glomeruli; ▪, VCAM-1 in the glomeruli.

Click to view
FIGURE 5
Renal gene activation in the Stx/LPS murine model. Shown are the nine most upregulated genes in the temporal response of mice to either LPS or Stx2. Gene microarrays were employed to analyze kidney gene activation over a 72-h response of C57BL/6 mice to 300 µg/kg of LPS or 100 ng/kg of Stx2.

Click to view
FIGURE 6
Metabolic and catabolic pathway enzymes for Gb3 synthesis. A part of Gb3 synthesis pathway is shown. From lactosylceramide (LacCer) to Gb3, alpha 1, 4-galactosyltransferase (EC 2.4.1.228) adds a galactose to LacCer to produce Gb3. Likewise, UDP-GalNAc: beta 1,3-galactosaminyltransferase (EC 2.4.1.79) works on Gb3 to make Gb4. In the catabolic pathway, beta-hexosaminidase (EC 3.2.1.52) degrades Gb4 to Gb3, and alpha-galactosidase (EC 3.2.1.22) makes LacCer from Gb3.
Tables

Click to view
TABLE 1
STEC oral administration model with CNS descriptions

Click to view
TABLE 2
Observed CNS symptoms in animal models a

Click to view
TABLE 3
Shiga toxin and/or LPS administration model with CNS descriptions
Supplemental Material
No supplementary material available for this content.